Consensus Recommendations on Initiating Prescription Therapies for Opioid-Induced Constipation

Abstract

ObjectiveAims of this consensus panel were to determine (1) an optimal symptom‐based method for assessing opioid‐induced constipation in clinical practice and (2) a threshold of symptom severity to prompt consideration of prescription therapy.MethodsA multidisciplinary panel of 10 experts with extensive knowledge/experience with opioid‐associated adverse events convened to discuss the literature on assessment methods used for opioid‐induced constipation and reach consensus on each objective using the nominal group technique.ResultsFive validated assessment tools were evaluated: the Patient Assessment of Constipation–Symptoms (PAC‐SYM), Patient Assessment of Constipation–Quality of Life (PAC‐QOL), Stool Symptom Screener (SSS), Bowel Function Index (BFI), and Bowel Function Diary (BF‐Diary). The 3‐item BFI and 4‐item SSS, both clinician administered, are the shortest tools. In published trials, the BFI and 12‐item PAC‐SYM are most commonly used. The 11‐item BF‐Diary is highly relevant in opioid‐induced constipation and was developed and validated in accordance with US Food and Drug Administration guidelines. However, the panel believes that the complex scoring for this tool and the SSS, PAC‐SYM, and 28‐item PAC‐QOL may be unfeasible for clinical practice. The BFI is psychometrically validated and responsive to changes in symptom severity; scores range from 0 to 100, with higher scores indicating greater severity and scores >28.8 points indicating constipation.ConclusionsThe BFI is a simple assessment tool with a validated threshold of clinically significant constipation. Prescription treatments for opioid‐induced constipation should be considered for patients who have a BFI score of ≥30 points and an inadequate response to first‐line interventions.

Colorectal Transit and Volume During Treatment With Prolonged-release Oxycodone/Naloxone Versus Oxycodone Plus Macrogol 3350

“…However, opioid treatment often results in substantial gastrointestinal (GI) side effects, collectively referred to as opioid-induced bowel dysfunction (OIBD). 1 These effects are mediated by binding of opioids to peripheral μ-opioid receptors in the gut, thereby disturbing normal GI motility and function. 2 The result is symptoms such as dry mouth, gastroesophageal reflux, vomiting, bloating, abdominal pain, anorexia, hard stools, and incomplete evacuation.…”

What Is New in Rome IV

“…Recently, peripherally acting µ-opioid antagonists (PAMORAs) that block the opioid receptors in the gastrointestinal tract but not centrally, have been developed. 62 …”

Opioid-induced constipation: advances and clinical guidance

“…Clinical guidance in care of patients with OIC related to noncancer pain Through a consensus document [Argoff et al 2015] from a group of experts, it is possible to propose a clinical guidance algorithm (Figure 3) for selection of OIC treatment. The first step involves the use of prophylactic treatment, with increase in water and fiber intake, and osmotic and stimulant laxatives.…”